NHS in England to offer pioneering cancer drug to patients with ‘Jolie gene’

NHS in England to offer pioneering cancer drug to patients with ‘Jolie gene’ Health watchdog reverses decision not to recommend olaparib for patients with genetic fault

The NHS in England is to offer thousands of cancer patients the world’s first cancer drug to target an inherited genetic fault, after a U-turn by the health watchdog.

The National Institute for Health and Care Excellence (Nice) opted last year not to recommend olaparib for breast cancer patients with the so-called “Angelina Jolie gene” because of its high cost. The pioneering drug’s list price is £2,317.50 for one pack of 150mg tablets, excluding VAT. The Guardian

See also:

• NHS strikes landmark deal for drug to treat two most common cancers NHS England
• Olaparib: Drug to treat inherited cancers offered on NHS in England and Wales BBC News
• Cancer patients to receive ‘life-changing’ AstraZeneca drug through NHS The Independent